ALX Oncology Holdings Inc.
ALXO
$2.11
-$0.07-3.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -31.28% | 12.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.23% | 3.94% | |||
| Operating Income | 26.23% | -3.94% | |||
| Income Before Tax | 15.62% | -5.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.62% | -5.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.62% | -5.46% | |||
| EBIT | 26.23% | -3.94% | |||
| EBITDA | 26.34% | -3.98% | |||
| EPS Basic | 15.77% | -4.36% | |||
| Normalized Basic EPS | 26.07% | -4.35% | |||
| EPS Diluted | 15.77% | -4.36% | |||
| Normalized Diluted EPS | 26.07% | -4.35% | |||
| Average Basic Shares Outstanding | 0.16% | 1.05% | |||
| Average Diluted Shares Outstanding | 0.16% | 1.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||